ExpreS2ion Biotech Holding is restructuring to reduce its workforce from 21 to five employees by 2027, aiming to lower annual operating costs by approximately SEK 30 million from 2028. While the move extends the company's cash runway, management confirms it does not fully fund operations beyond the Q1 2027 Phase I primary readout for its lead immunotherapy candidate, ES2B-C001.
The Board resolved a restructuring cutting staff from 21 to five during 2027, lowering operating costs by roughly SEK 23 million in 2027 and SEK 30 million annually from 2028 versus operating costs of SEK 56.5 million in 2025. This materially extends cash resources of SEK 35.8 million (31 October 2026), but the company explicitly states the measures do not finance operations beyond the Q1 2027 Phase I primary readout and financing terms are not guaranteed. Cost relief and financing risk largely offset, leaving the December 2026 translational readout and Q1 2027 Phase I data as the real price d
- • Workforce reduction from 21 to five employees with annual cost savings of approximately SEK 30 million from 2028
- • Translational study readout expected December 2026 and Phase I primary readout in Q1 2027
- • Restructuring does not by itself finance operations beyond the Phase I primary readout; financing may not be obtainable on acceptable terms
- • Restructuring costs of up to approximately SEK 5 million charged largely to Q4 2026